Press releases
- GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
- GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations
- DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
Tweets from GSK US
-
GSKUS @GSKUS
Our free #ScienceInTheSummer program teaches children how science is used in fields as varied as medicine, manufacturing, art, and environmental conservation. Stay tuned for announcements about our 34th season & Learn about the program: gsk.to/3cCmoIU #GSKSiS 🔭 🔬 👩
about 1 day ago
rcDr
-
GSKUS @GSKUS
For those living with #asthma and #severeasthma, take a look at this important guidance from @CDCemergency regarding #COVID19. twitter.com/CDCemergency/s…
about 1 day ago
-
GSKUS @GSKUS
TODAY: Don’t forget to join Dr. Len Friedland for the @mcclatchy @PhRMA livestream series "#COVID19: Bending the Curve” at 12:30 PM EDT. ✔️RSVP for this free event: view.ceros.com/mcclatchy/covi…
about 2 days ago
